Abstract
Introduction Practical difficulties in causality assessment for possible adverse drug reactions (ADRs) are a major source of uncertainty in clinical development, leading to different interpretations and handling procedures of ADRs across regions, in spite of the recent harmonized definition of ADRs. This study focused on how clinical investigators assess causality for adverse events (AEs) observed in clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
